# Piramal Pharma Limited Announces Results for Q2 and H1 FY27

- Link: https://www.thailand-business-news.com/pr-news/piramal-pharma-limited-announces-results-for-q2-and-h1-fy27
- Published: 2026-10-28T02:28:00+07:00
- Author: PR Newswire

|   |

MUMBAI, India, Oct. 28, 2026 /PRNewswire/ — Piramal Pharma Limited (NSE: PPLPHARMA
| BSE: 543635), a leading global pharmaceutical, health and wellness company, today
announced its standalone and consolidated results for the Second Quarter (Q2) and
Half Year (H1) ended 30^(th) September 2026.

  |

**Consolidated Financial Highlights**

  |  
 |

**_(in ₹ Crores or as stated)_**

  |  
 |

**Particulars**

  |

**Q2FY27**

  |

**Q2FY26**

  |

**YoY Growth**

  |

**H1FY27**

  |

**H1FY26**

  |

**YoY Growth**

  |  
 |

**Revenue from Operations**

  |

**2,617**

  |

**2,044**

  |

**28 %**

  |

**4,887**

  |

**3,977**

  |

**23 %**

  |  
 |

   _CDMO_

  |

1,424

  |

1,044

  |

36 %

  |

2,611

  |

2,041

  |

28 %

  |  
 |

   _CHG_

  |

849

  |

644

  |

32 %

  |

1,592

  |

1,281

  |

24 %

  |  
 |

   _PCH_

  |

359

  |

319

  |

13 %

  |

706

  |

621

  |

14 %

  |  
 |

**EBITDA**

  |

**385**

  |

**224**

  |

**72 %**

  |

**669**

  |

**389**

  |

**72 %**

  |  
 |

**EBITDA Margin **

  |

**14.7 %**

  |

**11.0 %**

  |    |

**13.7 %**

  |

**9.8 %**

  |    |  
 |

**PAT**

  |

**5**

  |

**(99)**

  |

**105 %**

  |

**(64)**

  |

**(181)**

  |

**64 %**

  |

**Key Highlights**

 ◦ **Broad-based Revenue Growth:** Revenue grew 28% YoY in Q2FY27 and 23% YoY in
   H1FY27, driven by strong performance across all three businesses.
 ◦ **Significant Profitability Improvement:** EBITDA increased 72% YoY in Q2FY27
   and H1FY27, with over 350bps EBITDA margin expansion in both periods. This was
   driven by higher capacity utilization, operating leverage, disciplined execution,
   and sustained cost optimization initiatives.
 ◦ **Robust RFP Activity and Order Inflows:** Added 22 new customers and successfully
   hosted 110 customer audits in H1FY27.
 ◦ **Best-in-Class Quality & Compliance:** Successfully completed 12 regulatory 
   inspections and 110 customer audits during H1FY27, while maintaining the Company’s
   track record of no Official Action Indicated classifications across US FDA inspections.
 ◦ **Upgrade FY27 Outlook:** Based on the strong first-half performance and continued
   business momentum, **we upgrade our FY27 outlook and now expect revenue growth
   of 19% to 20%, accompanied by meaningfully higher profitability**.

**Nandini Piramal, Chairperson, Piramal Pharma Limited** said, _"We delivered a 
strong H1FY27, with revenue growth of 23% and EBITDA margin expansion of over 350
basis points, driven by healthy demand across our businesses, disciplined execution,
and improved operating leverage. The performance was led by our CDMO business, which
grew 28% on the back of strong order inflows and robust execution. Our CHG business
complemented this momentum with 24% growth, supported by inhalation anesthesia sales
in ex-US markets and the integration of the Kenalog, while Consumer Healthcare continued
to deliver steady 14% growth through the strong performance of Power Brands and 
e-commerce._

_With H2 typically stronger than H1, we are well positioned to deliver a strong 
full-year performance, supported by a healthy order book, encouraging customer engagement,
and continued operating discipline."_

  |

**Key Business Highlights**

  |

  |

**Contract Development and Manufacturing Organization (CDMO):**

 ◦ **Robust Growth:** Broad-based growth across India and overseas sites, supported by healthy commercial demand, improved execution and disciplined cost management. India and North America led performance across the network.
 ◦ **Enhanced Profitability:** Better capacity utilization and operating leverage drove a meaningful improvement in profitability.
 ◦ **Strong Commercial Momentum:** Strong RFP activity and order inflows resulted in addition of 22 new customers during H1FY27. Phase III pipeline increased to 28 molecules from 25 as of March 2026.
 ◦ **Innovation and On-Patent Revenue Growth: **Innovation-related revenues grew 24%, while on-patent commercial manufacturing revenues grew 39% in H1FY27.
 ◦ **Differentiated Capabilities:** Strengthened biologics capabilities through acquisition of a controlling stake in Yapan Bio. The Lexington expansion remains on track, will add sterile fill-finish capabilities, completing the integrated ADC offering. Commissioned a new microbiology laboratory at the site.
 ◦ **ADC Services continued to gain momentum**, with revenues up 51% YoY in H1FY27.
 ◦ **Deepening Customer Engagement:** Successfully hosted 110 customer audits during H1FY27, reflecting continued customer engagement and confidence in the Company’s quality systems.

**Complex Hospital Generics (CHG):**

 ◦ **Inhalation Anesthesia Leadership:** Maintained leadership in the US Sevoflurane market with a 48% value share, while building traction in ex-US markets. (Source: IQVIA)
 ◦ **Kenalog® Integration:** Kenalog® contributed to CHG revenue during Q2FY27 and is expected to be an important growth driver for the business in FY27.
 ◦ **Intrathecal Therapy:** Maintained the #1 position in the US Intrathecal Baclofen market. (Source: IQVIA)
 ◦ **Injectable Pain Management:** Continued collaboration with suppliers to ensure product availability.
 ◦ **Building a Differentiated and Specialty Portfolio:** Continued investments in 505(b)(2) products, complex and differentiated generics, branded products, in-licensing and co-development to strengthen the long-term portfolio.

**Piramal Consumer Healthcare (PCH):**

 ◦ **Power Brands Continue to Outperform:** Power Brands grew 21% YoY in H1FY27, contributing 53% of PCH sales, reflecting the strength of the core portfolio.
 ◦ **Strong E-commerce Momentum:** Grew 32% YoY in H1FY27 and contributed 28% of PCH sales.
 ◦ **Innovation and Premiumization:** Continued focus on fewer, larger, and higher-potential launches to enhance portfolio quality and margins. Launched the ‘Vizible’ range under Lacto Calamine to strengthen presence in premium skincare.
 ◦ **Sustained Brand Investments:** Invested approximately 11% of PCH sales in media and trade promotion across digital and traditional channels to support long-term brand growth.
 ◦ **Bayer Distribution Agreement:** The distribution agreement will naturally expire in December 2026. The transition is being jointly managed to ensure business continuity, with no material impact expected on FY27 guidance.

  |

 

  |

**Consolidated Profit and Loss Statement**

  |  
 |

**_(in ₹ Crores or as stated)_**

  |  
 |

**Particulars**

  |

**Quarterly**

  |

**Half Yearly**

  |  
 |

**Q2FY27**

  |

**Q2FY26**

  |

**YoY**  **Change**

  |

**Q1FY26**

  |

**QoQ**  **Change**

  |

**H1FY27**

  |

**H1FY26**

  |

**YoY**  **Change**

  |  
 |

Revenue from Operations

  |

**2,617**

  |

**2,044**

  |

**28 %**

  |

**2,270**

  |

**15 %**

  |

**4,887**

  |

**3,977**

  |

**23 %**

  |  
 |

Other Income

  |

36

  |

66

  |

-45 %

  |

89

  |

(60) %

  |

125

  |

124

  |

1 %

  |  
 |

**Total Income**

  |

**2,653**

  |

**2,109**

  |

**26 %**

  |

**2,359**

  |

**12 %**

  |

**5,012**

  |

**4,101**

  |

**22 %**

  |  
 |

Material Cost

  |

906

  |

703

  |

29 %

  |

852

  |

6 %

  |

1,758

  |

1,397

  |

26 %

  |  
 |

Employee Expenses

  |

714

  |

611

  |

17 %

  |

676

  |

6 %

  |

1,390

  |

1,230

  |

13 %

  |  
 |

Other Expenses

  |

648

  |

571

  |

13 %

  |

547

  |

18 %

  |

1,195

  |

1,085

  |

10 %

  |  
 |

**EBITDA**

  |

**385**

  |

**224**

  |

**72 %**

  |

**285**

  |

**35 %**

  |

**669**

  |

**389**

  |

**72 %**

  |  
 |

Interest Expenses

  |

88

  |

82

  |

6 %

  |

88

  |

(1) %

  |

176

  |

169

  |

4 %

  |  
 |

Depreciation

  |

233

  |

203

  |

15 %

  |

224

  |

4 %

  |

457

  |

400

  |

14 %

  |  
 |

Share of Net Profit of Associates

  |

18

  |

15

  |

20 %

  |

20

  |

(9) %

  |

37

  |

33

  |

12 %

  |  
 |

**Profit Before Tax **

  |

**82**

  |

**(46)**

  |

**277 %**

  |

**(7)**

  |

**1,194 %**

  |

**74**

  |

**(146)**

  |

**151 %**

  |  
 |

Tax

  |

77

  |

53

  |

44 %

  |

62

  |

24 %

  |

139

  |

56

  |

149 %

  |  
 |

**Net Profit after Tax**

  |

**5**

  |

**(99)**

  |

**105 %**

  |

**(69)**

  |

**107 %**

  |

**(64)**

  |

**(202)**

  |

**68 %**

  |  
 |

Exceptional item1

  |

–

  |

–

  |

NA

  |

–

  |

NA

  |

–

  |

21

  |

**NA**

  |  
 |

**Net Profit after Tax after Exceptional Item**

  |

**5**

  |

**(99)**

  |

**105 %**

  |

**(69)**

  |

**107 %**

  |

**(64)**

  |

**(181)**

  |

**64 %**

  |

 1. Exceptional items include, one time insolvency proceeds received from a claim filed
    against a third-party supplier of our complex hospital generics business, with 
    the NCLT in November 2023

 

  |

**Consolidated Balance Sheet**

  |    |    |  
 |

_(in ₹ Cr. or as stated)_

  |  
 |

   **Key Balance Sheet Items**

  |

**As at**

  |  
 |

**30-Sep-26**

  |

**31-Mar-26**

  |  
 |

**Total Equity**

  |

8,165

  |

8,162

  |  
 |

Net Debt

  |

4,859

  |

4,164

  |  
 |

**Total**

  |

**13,023**

  |

**12,326**

  |  
 |    |    |    |  
 |

**Net Fixed Assets **

  |

**10,448**

  |

**9,784**

  |  
 |

    Tangible Assets

  |

4,923

  |

4,843

  |  
 |

    Intangible Assets including goodwill

  |

4,254

  |

3,841

  |  
 |

    CWIP (including IAUD2)

  |

1,271

  |

1,100

  |  
 |

Net Working Capital

  |

2,260

  |

2,081

  |  
 |

Other Assets3

  |

315

  |

462

  |  
 |

**Total Assets**

  |

**13,023**

  |

**12,326**

  |

**Earnings Conference Call**

Piramal Pharma Limited will be hosting a conference call for investors / analysts
on **28****^(th)**** October 2026 from 10:00 AM to 10:45 AM** **(IST)** **to discuss
its Q2 and H1 FY2027 Results.**

The dial-in details for the call are as under:

  |

**Event**

  |

**Location & Time**

  |

**Telephone Number**

  |  
 |

Conference call on 28^(th) October 2026

  |

India – 10:00 AM IST

  |

+91 22 6280 1461 / +91 22 7115 8320 (Primary Number)

  |  
 |

1 800 120 1221 (Toll free number)

  |  
 |

USA – 12:30 AM

(Eastern Time – New York)

  |

Toll free number

18667462133

  |  
 |

UK – 04:30 AM

(London Time)

  |

Toll free number

08081011573

  |  
 |

Singapore – 12:30 PM

(Singapore Time)

  |

Toll free number

8001012045

  |  
 |

Hong Kong – 12:30 PM

(Hong Kong Time)

  |

Toll free number

800964448

  |  
 |

Express Join with Diamond Pass™

  |

Please use this link for prior registration to reduce wait time at the time of joining the call –[Click here](https://clicktime.symantec.com/15x8NRbb3WmbhrWHEJwdN?h=lUhMojOhw8DNX-r3v1Wi_sMFqnl720WEy5_0aYBSfE8=&u=https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber%3D5748160%26linkSecurityString%3D326a0a84c0)

  |

**About Piramal Pharma Limited:**

Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of
differentiated products and services through its 17 global development and manufacturing
facilities and a global distribution network in over 100 countries. PPL includes
Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing
organization; Piramal Critical Care (PCC), a complex hospital generics business;
and the Piramal Consumer Healthcare (PCH) business, selling over-the-counter consumer
and wellness products. In addition, one of PPL’s associate companies, Abbvie Therapeutics
India Private Limited, a joint venture between Abbvie and PPL, has emerged as one
of the market leaders in the ophthalmology therapy area in the Indian pharma market.

For more information, visit:[ ](https://www.piramal.com/pharma/) [Piramal Pharma](https://www.piramalpharma.com/)
| [LinkedIn](https://www.linkedin.com/company/lifeatpiramalpharma/?viewAsMember=true)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Piramal Pharma Limited Announces Results for Q2 and H1 FY27 ](http://www.prnasia.com/story/archive/5082440_EN82440_0?rand=184833)